KPC Pharmaceutical (SHA:600422) recorded an attributable profit of 349.9 million yuan for the year 2025, down 46% from 648.1 million yuan a year prior, according to a Friday Hong Kong bourse filing by parent China Resources Pharmaceutical Group (HKG:3320).
Basic EPS stood at 0.46 yuan for the year, down from 0.86 yuan in the last corresponding period.
Operating revenue for the period slipped 22% to 6.58 billion yuan from 8.4 billion yuan in the year-ago period.
The downbeat results came about amid a decline in product sales and gross profit margin.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.